Download FREE Report Sample
Download Free sampleInsulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.
Biosimilar Insulin Glargine Market contains market size and forecasts of Biosimilar Insulin Glargine in global, including the following market information:
Global Biosimilar Insulin Glargine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Biosimilar Insulin Glargine Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Biosimilar Insulin Glargine companies in 2021 (%)
The global Biosimilar Insulin Glargine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Pre-filled Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Biosimilar Insulin Glargine include Eli Lilly, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Biosimilar Insulin Glargine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilar Insulin Glargine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Biosimilar Insulin Glargine Market Segment Percentages, by Type, 2021 (%)
Pre-filled
Cartridge
Global Biosimilar Insulin Glargine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Biosimilar Insulin Glargine Market Segment Percentages, by Application, 2021 (%)
Hospital
Retail Pharmacy
Others
Global Biosimilar Insulin Glargine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Biosimilar Insulin Glargine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilar Insulin Glargine revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Biosimilar Insulin Glargine revenues share in global market, 2021 (%)
Key companies Biosimilar Insulin Glargine sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Biosimilar Insulin Glargine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
